This year's World Congress of Anaesthesiologists in Singapore marked a significant milestone with the official Asia launch of Deltex's ground-breaking TrueVue™ Doppler haemodynamic monitoring system.

The TrueVue™ system seamlessly integrates over 40 years of ultrasound expertise and indisputable clinical evidence, offering unmatched precision and reliability. Utilizing the latest state-of-the-art technologies, the TrueVue Monitor not only combines blood flow and flow-calibrated blood pressure data but also features a new and intuitive user interface, customizable display options, battery operation, and much more.

During the congress, an Asian distributors meeting was organized with the support of Pacific Medical Systems Ltd. (PMS), senior representatives from Deltex, and key opinion leaders in the field of haemodynamic monitoring. The meeting proved to be energizing and educational, leaving Deltex's Asia Distributors highly motivated and eager to introduce the new TrueVue monitor in the region.

Andy Mears, CEO of Deltex Medical UK, expressed his enthusiasm for the collaboration with Pacific Medical Systems, stating, "We are thrilled to be working closely with PMS to bring the new TrueVue system to Asia. In high-pressure operating and critical care environments, clinicians may perceive haemodynamic monitoring as a luxury. However, evidence shows that patient outcomes, both short and long-term, are significantly improved when the patient is in an optimal haemodynamic state. Only TrueVue, with its unique Oesophageal Doppler Monitoring (ODM) technology, can provide the accurate, precise, and powerful real-time information that anaesthesiologists and intensivists need to guide their fluid and drug interventions. With its enhanced user-friendliness and portability between clinical settings, the benefits for patients are now within reach, leading to better outcomes, increased efficiency, and lower costs."

Jules Flach, CEO of Pacific Medical Systems Limited, also expressed confidence in the collaboration, stating, "By combining our extensive knowledge and experience in promoting ultrasound technologies in Anaesthesia, Critical and Point of Care with Deltex's leading haemodynamic monitoring system, supported by 24 randomized controlled trials (RCTs) and over 80% of the positive supporting evidence, we are well-equipped and excited to penetrate the market and increase awareness and adoption of Deltex products in our geography."